These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 23438962)
1. Cyclophilins in atherosclerosis: a new therapeutic target? Bukrinsky M; Orekhov A; Ditiatkovski M; Sviridov D Curr Pharm Des; 2013; 19(33):5904-8. PubMed ID: 23438962 [TBL] [Abstract][Full Text] [Related]
2. Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics. Yurchenko V; Constant S; Eisenmesser E; Bukrinsky M Clin Exp Immunol; 2010 Jun; 160(3):305-17. PubMed ID: 20345978 [TBL] [Abstract][Full Text] [Related]
3. Importance of receptor-targeted systems in the battle against atherosclerosis. Rosas E; Sobenin I; Orekhov A; Edelman ER; Balcells M Curr Pharm Des; 2013; 19(33):5897-903. PubMed ID: 23438961 [TBL] [Abstract][Full Text] [Related]
7. Extracellular cyclophilins in health and disease. Bukrinsky M Biochim Biophys Acta; 2015 Oct; 1850(10):2087-95. PubMed ID: 25445705 [TBL] [Abstract][Full Text] [Related]
8. Non-Invasive Detection of Extracellular Matrix Metalloproteinase Inducer EMMPRIN, a New Therapeutic Target against Atherosclerosis, Inhibited by Endothelial Nitric Oxide. Ramirez-Carracedo R; Tesoro L; Hernandez I; Diez-Mata J; Filice M; Toro R; Rodriguez-Piñero M; Zamorano JL; Saura M; Zaragoza C Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347750 [TBL] [Abstract][Full Text] [Related]
9. Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic Approaches. Park KH; Park WJ J Korean Med Sci; 2015 Sep; 30(9):1213-25. PubMed ID: 26339159 [TBL] [Abstract][Full Text] [Related]
10. Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets. Ramji DP; Davies TS Cytokine Growth Factor Rev; 2015 Dec; 26(6):673-85. PubMed ID: 26005197 [TBL] [Abstract][Full Text] [Related]
11. Crosstalk between cyclophilins and T lymphocytes in coronary artery disease. Gegunde S; Alfonso A; Alvariño R; Alonso E; González-Juanatey C; Botana LM Exp Cell Res; 2021 Mar; 400(2):112514. PubMed ID: 33582093 [TBL] [Abstract][Full Text] [Related]
17. Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH). Ure DR; Trepanier DJ; Mayo PR; Foster RT Expert Opin Investig Drugs; 2020 Feb; 29(2):163-178. PubMed ID: 31868526 [No Abstract] [Full Text] [Related]
18. Matrix-metalloproteinases as imaging targets for inflammatory activity in atherosclerotic plaques. Schäfers M; Schober O; Hermann S J Nucl Med; 2010 May; 51(5):663-6. PubMed ID: 20439506 [TBL] [Abstract][Full Text] [Related]
19. The role of T and B cells in atherosclerosis: potential clinical implications. Dumitriu IE; Kaski JC Curr Pharm Des; 2011 Dec; 17(37):4159-71. PubMed ID: 22204376 [TBL] [Abstract][Full Text] [Related]
20. Role of endothelial cell-derived angptl2 in vascular inflammation leading to endothelial dysfunction and atherosclerosis progression. Horio E; Kadomatsu T; Miyata K; Arai Y; Hosokawa K; Doi Y; Ninomiya T; Horiguchi H; Endo M; Tabata M; Tazume H; Tian Z; Takahashi O; Terada K; Takeya M; Hao H; Hirose N; Minami T; Suda T; Kiyohara Y; Ogawa H; Kaikita K; Oike Y Arterioscler Thromb Vasc Biol; 2014 Apr; 34(4):790-800. PubMed ID: 24526691 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]